急性和慢性白血病患者血浆中循环蛋白酶体胰凝乳蛋白酶样活性的评估。
Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias.
作者信息
Ostrowska Halina, Hempel Dominika, Holub Malgorzata, Sokolowski Jaroslaw, Kloczko Janusz
机构信息
Department of Biology, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland.
出版信息
Clin Biochem. 2008 Nov;41(16-17):1377-83. doi: 10.1016/j.clinbiochem.2008.08.063. Epub 2008 Aug 22.
OBJECTIVE
We evaluated whether the proteasomal chymotrypsin-like (ChT-L) activity is increased in plasma of patients with acute lymphoblastic (ALL), acute myeloblastic (AML) and chronic lymphocytic (CLL) leukemias.
METHODS
The activity was assayed using the fluorogenic peptide substrate in the presence of an artificial activator sodium dodecyl sulfate (SDS) in the plasma of healthy donors (n=15) and ALL (n=15), AML (n=28) and CLL (n=22) patients.
RESULTS
The activity was significantly (P<0.001) higher in the plasma of ALL and AML patients at the diagnosis than in healthy subjects and decreased after therapy or remained unchanged or rose during relapse. By contrast, in CLL patients at the diagnosis, the activity did not differ significantly from the healthy controls. In each group, the activity positively correlated with the serum lactic dehydrogenase activity.
CONCLUSIONS
Plasma proteasome ChT-L activity can be a useful bio-marker for patients with acute leukemia at the blast stage.
目的
我们评估了急性淋巴细胞白血病（ALL）、急性髓细胞白血病（AML）和慢性淋巴细胞白血病（CLL）患者血浆中蛋白酶体类胰凝乳蛋白酶样（ChT-L）活性是否升高。
方法
在健康供者（n = 15）以及ALL（n = 15）、AML（n = 28）和CLL（n = 22）患者的血浆中，使用荧光肽底物并在人工激活剂十二烷基硫酸钠（SDS）存在的情况下测定该活性。
结果
ALL和AML患者诊断时血浆中的活性显著高于健康受试者（P < 0.001），治疗后活性降低，或在复发期间保持不变或升高。相比之下，CLL患者诊断时的活性与健康对照无显著差异。在每组中，该活性与血清乳酸脱氢酶活性呈正相关。
结论
血浆蛋白酶体ChT-L活性可能是处于原始细胞阶段的急性白血病患者的一种有用生物标志物。
Zotero 插件